EuroBiotech: More Articles of Note


> Nordic Nanovector delayed the readout from its phase 2b follicular lymphoma trial in response to slow patient enrollment. The delay moves the readout beyond when analysts at Jefferies expect the biotech’s current cash reserves to run dry. Release 

> PPF bought a 19.2% stake in CAR-T biotech Autolus. The Czech investment group owns most of another biotech, Sotio. Statement

> Lytix Biopharma appointed Øystein Rekdal as CEO. Rekdal replaces Edwin Klumper, who is taking early retirement. Release


Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

> Poxel shared detailed data from a Japanese phase 3 trial of imeglimin in Type 2 diabetics. Metavant has the rights to the drug in the U.S. and Europe. Statement 

> Theranexus enrolled the last subject in a phase 1b trial of its treatment of neurocognitive disorders related to Alzheimer's disease. Release 

> Ose Immunotherapeutics received a €5.4 million ($6 million) milestone payment in relation to its Boehringer Ingelheim-partnered SIRPa-antagonist and myeloid checkpoint inhibitor. Statement 

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.